Eli Lilly's new long-acting amylin receptor agonist, eloralintide, has received approval from China's Center for Drug Evaluation to conduct three pivotal global Phase 3 clinical trials in the country. The studies are intended to support future regulatory submissions in China for multiple indications, including weight management, addressing the clinical needs of patients with obesity or overweight and related comorbidities by offering effective and well-tolerated treatment options. Eloralintide is a potent, selective, long-acting agonist of the amylin receptor that binds with high affinity to the human amylin type 1 receptor while maintaining selectivity for the human calcitonin receptor. This mechanism helps sustain weight loss effects while improving gastrointestinal tolerability, achieving a balance between efficacy and safety. The selectivity of eloralintide for the amylin receptor may reduce potential risks associated with calcitonin receptor activity. With a long plasma half-life of approximately 14 days, the drug is suitable for once-weekly subcutaneous administration. Eloralintide is being developed for the following uses: as an adjunct to diet and exercise for long-term weight management in adults with obesity or overweight who have at least one weight-related comorbidity; and as part of combination therapy for long-term weight management in adults who have not achieved treatment goals while on stable doses of incretin-based medications.